TY - JOUR
T1 - Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck
AU - Colella, E.
AU - Merlano, M.
AU - Blengio, F.
AU - Angelini, F.
AU - Ausili Cefaro, G. P.
AU - Scasso, F.
AU - Lo Russo, V.
AU - Cirulli, S.
AU - Giannarelli, D.
AU - Cognetti, F.
PY - 1994
Y1 - 1994
N2 - Between March 1990 and March 1992, 89 patients with recurrent and/or metastatic squamous cell cancer of the head and neck were randomised to receive either intravenous methotrexate (MTX) at a weekly dose of 40 mg/m2 plus lonidamine (LND) given orally at a starting dose of 75 mg three times daily for 3 days and then at a dose of 150 mg three times daily (arm MTX+LND) or methotrexate alone (arm MTX) at the same doses as arm MTX+LND. Complete remissions were observed in 10.5% of the patients in arm MTX+LND, and partial remissions in another 15.8%, yielding a 26.3% response rate. In arm MTX, only partial remissions were observed, yielding an overall response rate of 18.2%. Haematological toxicity was mild in both groups. Mild testicular pain (21%) and myalgias (31%) occurred only in patients treated with LND.
AB - Between March 1990 and March 1992, 89 patients with recurrent and/or metastatic squamous cell cancer of the head and neck were randomised to receive either intravenous methotrexate (MTX) at a weekly dose of 40 mg/m2 plus lonidamine (LND) given orally at a starting dose of 75 mg three times daily for 3 days and then at a dose of 150 mg three times daily (arm MTX+LND) or methotrexate alone (arm MTX) at the same doses as arm MTX+LND. Complete remissions were observed in 10.5% of the patients in arm MTX+LND, and partial remissions in another 15.8%, yielding a 26.3% response rate. In arm MTX, only partial remissions were observed, yielding an overall response rate of 18.2%. Haematological toxicity was mild in both groups. Mild testicular pain (21%) and myalgias (31%) occurred only in patients treated with LND.
KW - chemotherapy
KW - head and neck cancer
KW - lonidamine
UR - http://www.scopus.com/inward/record.url?scp=0027990705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027990705&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(94)90116-3
DO - 10.1016/0959-8049(94)90116-3
M3 - Article
C2 - 7946585
AN - SCOPUS:0027990705
SN - 0959-8049
VL - 30
SP - 928
EP - 930
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 7
ER -